Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: Review of the literature

Dermatologic Surgery

Volumn 38, Issue 6, 2012, Pages 937-946

  Ellis, Lixia Z ^a   Cohen, Joel L ^a,c   High, Whitney ^a,b   Stewart, Leslie ^d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c AboutSkin Dermatology and DermSurgery PC   (United States)

^d Adult and Pediatric Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

AGED; CASE REPORT; CRYOTHERAPY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPLASTIC NEVUS; ERYTHEMA; EXCISION; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MELANOMA; MELANOMA IN SITU; METASTATIC MELANOMA; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BIOPSY; FACIAL NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MOHS SURGERY; SKIN NEOPLASMS;

EID: 84861823282     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02362.x     Document Type: Review

References (110)

1. Weinstock MA, Sober AJ,. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116: 303-10.
2. Osborne JE, Hutchinson PE,. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg 2002; 55: 611-5.
3. Bub JL, Berg D, Slee A, Odland PB,. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol 2004; 140: 552-8.
4. Cohen LM, McCall MW, Zax RH,. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg 1998; 24: 673-7.
5. Agarwal-Antal N, Bowen GM, Gerwels JW,. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47: 743-8.
6. Wayte DM, Helwig EB,. Melanotic freckle of Hutchinson. Cancer 1968; 21: 893-911.
7. Mocellin S, Nitti D,. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist 2011; 16: 896-903.
8. Erickson C, Miller SJ,. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol 2010; 49: 482-91.
9. Farshad A, Burg G, Panizzon R, Dummer R,. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-6.
10. Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43: 477-82.
11. Tsang RW, Liu FF, Wells W, Payne DG,. Lentigo maligna of the head and neck. RESULTS: of treatment by radiotherapy. Arch Dermatol 1994; 130: 1008-12.
12. Zalaudek I, Horn M, Richtig E, Hodl S, et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol 2003; 148: 703-8.
13. Harwood AR,. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983; 9: 1019-21.
14. Mahendran RM, Newton-Bishop JA,. Survey of U.K. current practice in the treatment of lentigo maligna. Br J Dermatol 2001; 144: 71-6.
15. Kuflik EG, Gage AA,. Cryosurgery for lentigo maligna. J Am Acad Dermatol 1994; 31: 75-8.
16. Dawber RP, Wilkinson JD,. Melanotic freckle of Hutchinson: treatment of macular and nodular phases with cryotherapy. Br J Dermatol 1979; 101: 47-9.
17. Zacarian SA,. Cryosurgical treatment of lentigo maligna. Arch Dermatol 1982; 118: 89-92.
18. Bohler-Sommeregger K, Schuller-Petrovic S, Neumann R, Muller E,. Cryosurgery of lentigo maligna. Plast Reconstr Surg 1992; 90: 436-40. discussion 41-4.
19. Bohler-Sommeregger K, Schuller-Petrovic S, Knobler R, Neumann PR,. Reactive lentiginous hyperpigmentation after cryosurgery for lentigo maligna. J Am Acad Dermatol 1992; 27: 523-6.
20. Collins P, Rogers S, Goggin M, Manning W,. Cryotherapy for lentigo maligna. Clin Exp Dermatol 1991; 16: 433-5.
21. McLeod M, Choudhary S, Giannakakis G, Nouri K,. Surgical treatments for lentigo maligna: a review. Dermatol Surg 2011; 37: 1210-28.
22. Toren KL, Parlette EC,. Managing melanoma in situ. Semin Cutan Med Surg 2010; 29: 258-63.
23. Schon MP, Schon M,. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27: 190-9.
24. Reiter MJ, Testerman TL, Miller RL, Weeks CE, et al. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 1994; 55: 234-40.
25. Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995; 15: 537-45.
26. Gibson SJ, Lindh JM, Riter TR, Gleason RM, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.
27. Megyeri K, Au WC, Rosztoczy I, Raj NB, et al. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 1995; 15: 2207-18.
28. Weeks CE, Gibson SJ,. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994; 14: 81-5.
29. Wagner TL, Horton VL, Carlson GL, Myhre PE, et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 1997; 9: 837-45.
30. Schon MP, Schon M, Klotz KN,. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 2006; 126: 1338-47.
31. Wolf IH, Kodama K, Cerroni L, Kerl H,. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol 2007; 29: 237-41.
32. Schon MP, Wienrich BG, Drewniok C, Bong AB, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266-76.
33. Schon M, Bong AB, Drewniok C, Herz J, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.
34. Berman B, Sullivan T, De Araujo T, Nadji M,. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003; 149 (Suppl 66): 59-61.
35. De Giorgi V, Salvini C, Chiarugi A, Paglierani M, et al. In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol 2009; 48: 312-21.
36. Hesling C, D'Incan M, Mansard S, Franck F, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004; 150: 761-7.
37. Li VW, Li WW, Talcott KE, Zhai AW,. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005; 4: 708-17.
38. Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, et al. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005; 44: 14-9.
39. Missall TA, Hurley MY, Fosko SW,. Lentiginous melanoma in situ treatment with topical imiquimod: need for individualized regimens. Arch Dermatol 2010; 146: 1309-10.
40. Van Meurs T, Van Doorn R, Kirtschig G,. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients. Dermatol Surg 2010; 36: 853-8.
41. Powell AM, Robson AM, Russell-Jones R, Barlow RJ,. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 2009; 160: 994-8.
42. Curiel-Lewandrowski C, Williams CM, Swindells KJ, Tahan SR, et al. Use of in vivo confocal microscopy in malignant melanoma: an aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches. Arch Dermatol 2004; 140: 1127-32.
43. Martires KJ, Capaldi L, Pattee SF, Maloney ME, et al. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Arch Dermatol 2010; 146: 1047-8.
44. Powell AM, Russell-Jones R,. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol 2004; 50: 792-6.
45. Cotter MA, McKenna JK, Bowen GM,. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008; 34: 147-51.
46. Fleming CJ, Bryden AM, Evans A, Dawe RS, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004; 151: 485-8.
47. Kowalzick L, Eickenscheidt L,. Progress of multiple cutaneous and subcutaneous melanoma metastases of the face during imiquimod treatment. J Dtsch Dermatol Ges 2009; 7: 538-40.
48. Miller AK, Dusing R, Meggison A, Aires D,. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin. J Drugs Dermatol 2011; 10: 302-5.
49. Florin V, Desmedt E, Vercambre-Darras S, Mortier L,. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 2011; Jul 13. [Epub ahead of print.].
50. Steinmann A, Funk JO, Schuler G, von den Driesch P,. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43: 555-6.
51. Utikal J, Zimpfer A, Thoelke A, Figl R, et al. Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br J Dermatol 2006; 155: 488-91.
52. Nagore E, Botella-Estrada R, Sanmartin O, Guillen C,. Imiquimod for the treatment of skin metastases of melanoma. Actas Dermosifiliogr 2005; 96: 549-50.
53. Bong AB, Bonnekoh B, Franke I, Schon MP, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002; 205: 135-8.
54. Loquai C, Nashan D, Metze D, Beiteke U, et al. Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases. Hautarzt 2004; 55: 176-81.
55. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD,. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156: 337-45.
56. Garcia MS, Ono Y, Martinez SR, Chen SL, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res 2011; 21: 235-43.
57. Zeitouni NC, Dawson K, Cheney RT,. Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser. Br J Dermatol 2005; 152: 376-7.
58. Florin V, Vercambre-Darras S, Piette F, Mortier L,. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Ann Dermatol Venereol 2008; 135: 603-4.
59. Shistik G, Prakash AV, Fenske NA, Glass LF,. Treatment of locally metastatic melanoma: a novel approach. J Drugs Dermatol 2007; 6: 830-2.
60. Naylor MF, Chen WR, Teague TK, Perry LA, et al. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol 2006; 155: 1287-92.
61. Li X, Naylor MF, Le H, Nordquist RE, et al. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. Cancer Biol Ther 2010; 10: 1081-7.
62. Spieth K, Kovacs A, Wolter M, Bug R, et al. Topical imiquimod: effectiveness in intraepithelial melanoma of oral mucosa. Lancet Oncol 2006; 7: 1036-7.
63. Zattra E, Salmaso R, Tonin E, Alaibac M,. Achromic superficial spreading melanoma accidentally treated with imiquimod. Acta Derm Venereol 2012; 92: 107-8.
64. Dusza SW, Delgado R, Busam KJ, Marghoob AA, et al. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol 2006; 5: 56-62.
65. Somani N, Martinka M, Crawford RI, Dutz JP, et al. Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol 2007; 143: 379-85.
66. Ahmed I, Berth-Jones J,. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143: 843-5.
67. Chapman MS, Spencer SK, Brennick JB,. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003; 139: 943-4.
68. Epstein E,. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 2003; 139: 944-5.
69. Fisher GH, Lang PG,. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 2003; 139: 945-7.
70. Borucki U, Metze D,. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology 2003; 207: 326-8.
71. Naylor MF, Crowson N, Kuwahara R, Teague K, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 (Suppl 66): 66-70.
72. Powell AM, Russell-Jones R, Barlow RJ,. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004; 29: 15-21.
73. Kupfer-Bessaguet I, Guillet G, Misery L, Carre JL, et al. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. J Am Acad Dermatol 2004; 51: 635-9.
74. Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, et al. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol 2004; 151: 903-6.
75. Munoz CM, Sanchez JL, Martin-Garcia RF,. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 2004; 30: 1543-5.
76. Kamin A, Eigentler TK, Radny P, Bauer J, et al. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol 2005; 52: 51-2.
77. Wolf IH, Cerroni L, Kodama K, Kerl H,. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005; 141: 510-4.
78. Ray CM, Kluk M, Grin CM, Grant-Kels JM,. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 2005; 44: 428-34.
79. Lorentzen HF, Weismann K,. Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance. Ugeskr Laeger 2005; 167: 3696-7.
80. Martin T, Ojeda A, Martinez S, Vera A,. Lentigo maligna treated with 5% imiquimod cream. Actas Dermosifiliogr 2005; 96: 700-2.
81. Micantonio T, Fargnoli MC, Peris K,. Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna. Arch Dermatol 2006; 142: 530-1.
82. Lonsdale-Eccles AA, Morgan JM, Nagarajan S, Cruickshank DJ,. Successful treatment of vulval melanoma in situ with topical 5% imiquimod cream. Br J Dermatol 2006; 155: 215-7.
83. Spenny ML, Walford J, Werchniak AE, Beltrani V, et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007; 79: 149-52.
84. van Meurs T, van Doorn R, Kirtschig G,. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg 2007; 33: 623-6.
85. du Plessis PJ,. Lentigo maligna successfully treated with imiquimod. S Afr J Surg 2007; 45: 72.
86. Murchison AP, Washington CV, Soloman AR, Bernardino CR,. Ocular effects of imiquimod with treatment of eyelid melanoma in situ. Dermatol Surg 2007; 33: 1136-8.
87. Hopson B, Richey D, Sajben FP,. Treatment of lentigo maligna with imiquimod 5% cream. J Drugs Dermatol 2007; 6: 1037-40.
88. Bassukas ID, Gamvroulia C, Zioga A, Nomikos K, et al. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. Int J Dermatol 2008; 47: 519-21.
89. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE,. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 2008; 144: 943-5.
90. de Troya-Martin M, Frieyro-Elicegui M, Funez Liebana R, Aguilar Bernier M, et al. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases. Dermatol Surg 2008; 34: 1561-6.
91. Micali G, Lacarrubba F, Nardone B, Nasca MR,. Videodermatoscopy of lentigo maligna treated with imiquimod. J Drugs Dermatol 2008; 7: 1077-80.
92. Mahoney MH, Joseph MG, Temple C,. Topical imiquimod therapy for lentigo maligna. Ann Plast Surg 2008; 61: 419-24.
93. Ventura F, Rocha J, Fernandes JC, Pardal F, et al. Topical imiquimod treatment of lentigo maligna. Case Rep Dermatol 2009; 1: 78-81.
94. Ramsdell AM, Zeitouni N,. Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod. Dermatol Surg 2009; 35: 287-90.
95. Piazza CD, Sampaio SA,. Remission of extensive lentigo maligna after treatment with imiquimod. An Bras Dermatol 2009; 84: 82-4.
96. Missall TA, Fosko SW,. The use of imiquimod to minimize the surgical defect when excising invasive malignant melanoma surrounded by extensive melanoma in situ, lentiginous type. Dermatol Surg 2009; 35: 868-74.
97. Woodmansee C, Pillow J, Skinner RB Jr,. The role of topical immune response modifiers in skin cancer. Drugs 2006; 66: 1657-64.
98. Nadiminti H, Scope A, Marghoob AA, Busam K, et al. Use of reflectance confocal microscopy to monitor response of lentigo maligna to nonsurgical treatment. Dermatol Surg 2010; 36: 177-84.
99. Cheikhrouhou H, Pouaha J, Claeys A, Truchetet F,. Topical imiquimod as palliative therapy for extensive lentigo maligna on the cheek. Ann Dermatol Venereol 2010; 137: 142-4.
100. Demirci H, Shields CL, Bianciotto CG, Shields JA, et al. Topical imiquimod for periocular lentigo maligna. Ophthalmology 2010; 117: 2424-9.
101. Sadownik LA, Crawford RI,. Post-surgical treatment of melanoma in situ of the vulva with imiquimod. J Obstet Gynaecol Can 2010; 32: 771-4.
102. Rodriguez-Martin M, Rodriguez-Martin J, de Paz NM, Ferrer PC, et al. Conjunctival melanoma: a new clinical and therapeutical approach. Case Rep Dermatol 2010; 2: 149-55.
103. O'Neill J, Ayers D, Kenealy J,. Periocular lentigo maligna treated with imiquimod. J Dermatolog Treat 2011; 22: 109-12.
104. Ugurel S, Wagner A, Pfohler C, Tilgen W, et al. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002; 147: 621-4.
105. Vereecken P, Mathieu A, Laporte M, Petein M, et al. Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod. Dermatology 2003; 206: 279-80.
106. Wolf IH, Smolle J, Binder B, Cerroni L, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139: 273-6.
107. Siguenza M, Pizarro A, Mayor M, Vidaurrazaga C, et al. Topical treatment of melanoma skin metastases with imiquimod. Actas Dermosifiliogr 2005; 96: 111-5.
108. Heber G, Helbig D, Ponitzsch I, Wetzig T, et al. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy. J Dtsch Dermatol Ges 2009; 7: 534-6.
109. Turza K, Dengel LT, Harris RC, Patterson JW, et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 2010; 37: 94-8.
110. Tiodorovic-Zivkovic D, Argenziano G, Catricala C, Ferrara G, et al. Adjuvant treatment with topical 5% imiquimod cream for resected stage IIIb melanoma. Eur J Dermatol 2011; 21: 410-1.